RxDoctor Payments Data

Russell Daily, PA

Physician Assistant · Keller, TXNPI 1881748432

Payments from drug & device makers

$14,865in general payments, 2019–2025

Across 893 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$878
  • Axsome Therapeutics, Inc.$764
  • Otsuka America Pharmaceutical, Inc.$550
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$14,853100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie117$1,829
AstraZeneca46$1,067
Novo Nordisk85$1,040
Pfizer49$878
Axsome Therapeutics, Inc.40$764
Otsuka America Pharmaceutical, Inc.39$550
Amgen(2 entities)40$542
Corium, LLC22$516
Boehringer Ingelheim32$514
Antares Pharma, Inc.27$455
Lilly USA, LLC27$403
GSK20$388
Scilex Pharmaceuticals Inc.20$378
Johnson & Johnson22$347
Supernus Pharmaceuticals, Inc.10$294
Corcept Therapeutics13$273
Bayer25$269
Esperion Therapeutics, Inc.16$237
Takeda Pharmaceuticals U.S.A., Inc.12$215
Merck12$191
Upsher-smith Laboratories LLC11$182
Biohaven Pharmaceuticals, Inc.11$181
Kowa Pharmaceuticals America, Inc.11$172
Phathom Pharmaceuticals, Inc.4$168
Biohaven Pharmaceutical Holding Company Ltd.13$163
Optinose US, Inc.13$152
Impel Pharmaceuticals Inc.11$145
Nabriva Therapeutics, PLC9$129
Daiichi Sankyo Inc.6$119
Lundbeck LLC6$103
Medtronic1$101
Tris Pharma Inc6$100
Almatica Pharma LLC6$98
Novartis6$98
Jazz Pharmaceuticals Inc.5$95
Arbor Pharmaceuticals, Inc.6$88
IBSA Pharma Inc.6$87
Abbott5$87
Eisai Inc.4$80
Halozyme Inc4$79
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$68
Sanofi-aventis U.S. LLC3$64
E.r. Squibb & Sons, L.L.C.4$62
Xeris Pharmaceuticals, Inc.3$62
Clarus Therapeutics Inc.4$60
Noven Therapeutics, LLC3$51
Dexcom, Inc.3$50
Azurity Pharmaceuticals, Inc.3$47
Amneal Pharmaceuticals LLC3$47
Penumbra, Inc.1$46
Averitas Pharma Inc.1$45
Genentech USA, Inc.6$45
Tolmar, Inc.3$44
Mayne Pharma Commercial LLC2$44
Verity Pharmaceuticals Inc.2$44
Astellas Pharma US Inc2$40
Idorsia Pharmaceuticals US Inc2$37
Bausch Health US, LLC2$36
Paratek Pharmaceuticals, Inc.2$34
Kaleo, Inc.2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,865 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$39,117
Medicare patients
234
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$42,359
EliquisApixaban26$30,594
MounjaroTirzepatide20$20,610
FarxigaDapagliflozin Propanediol15$20,063
KerendiaFinerenone11$11,581
Estradiol12$1,825
Tamsulosin Hcl90$1,661
Levothyroxine Sodium122$1,539
Celecoxib42$1,524
Rosuvastatin Calcium117$1,452
PaxlovidNirmatrelvir/Ritonavir13$1,429
Gabapentin49$1,315
Atorvastatin Calcium109$1,050
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide13$915
Metoprolol Succinate62$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,040$42,35939 claims
PfizerEliquis, Paxlovid$878$32,02339 claims
Lilly USA, LLCMounjaro$403$20,61020 claims
AstraZenecaFarxiga$1,067$20,06315 claims
BayerKerendia$269$11,58111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$47$1,539122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Keller

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →